Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus (RSV) is a common respiratory virus that affects people of all ages. It is especially dangerous for infants and older adults, as it can lead to severe respiratory illness. However, there is good news on the horizon. Health Canada has recently approved a vaccine to protect both infants and older adults from RSV.

This newly approved vaccine is a significant breakthrough in the fight against RSV. It can be administered to pregnant women, providing protection to their unborn babies. By immunizing infants early on, we can greatly reduce the risk of severe respiratory illness caused by RSV. Additionally, older adults, who are also vulnerable to RSV, can benefit from this vaccine.

RSV is a highly contagious virus that spreads through respiratory droplets. It can cause symptoms such as cough, runny nose, fever, and difficulty breathing. In severe cases, it can lead to pneumonia or bronchiolitis, especially in infants. With the approval of this vaccine, we now have a powerful tool to prevent RSV infection and its potentially devastating consequences.